A new approach for heparin standardization: combination of scanning UV spectroscopy, nuclear magnetic resonance and principal component analysis.
The year 2007 was marked by widespread adverse clinical responses to heparin use, leading to a global recall of potentially affected heparin batches in 2008. Several analytical methods have since been developed to detect impurities in heparin preparations; however, many are costly and dependent on instrumentation with only limited accessibility. A method based on a simple UV-scanning assay, combined with principal component analysis (PCA), was developed to detect impurities, such as glycosaminoglycans, other complex polysaccharides and aromatic compounds, in heparin preparations. Results were confirmed by NMR spectroscopy. This approach provides an additional, sensitive tool to determine heparin purity and safety, even when NMR spectroscopy failed, requiring only standard laboratory equipment and computing facilities.
Departamento de Bioquímica, Disciplina de Biologia Molecular, Universidade Federal de São Paulo, São Paulo, Brazil.
Marcelo A
MA
Lima
Timothy R
TR
Rudd
Eduardo H C
EH
de Farias
Lyvia F
LF
Ebner
Tarsis F
TF
Gesteira
Lauro M
LM
de Souza
Aline
A
Mendes
Carolina R
CR
Córdula
João R M
JR
Martins
Debra
D
Hoppensteadt
Jawed
J
Fareed
Guilherme L
GL
Sassaki
Edwin A
EA
Yates
Ivarne L S
IL
Tersariol
Helena B
HB
Nader
D004340:Drug Contamination; D064420:Drug-Related Side Effects and Adverse Reactions; D006493:Heparin / Q000592:standards*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008722:Methods; D025341:Principal Component Analysis; D012015:Reference Standards; D013056:Spectrophotometry, Ultraviolet / Q000379:methods
D006493:Heparin
Nat Biotechnol. 2008 Jun;26(6):669-75
18437154
Pharmeuropa Bio. 2008 Dec;2008(1):31-9
19220979
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):16956-61
19805108
N Engl J Med. 1982 Nov 25;307(22):1384-8
7133084
J Pharm Biomed Anal. 2010 Mar 11;51(4):921-6
19959313
Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):395-401
19617248
Carbohydr Res. 1971 Jun;18(2):185-94
5151386
Carbohydr Res. 1988 Dec 31;184:292-300
2977295
J Clin Pathol. 1955 Aug;8(3):247-8
13252109
Fed Proc. 1977 Jan;36(1):19-24
137128
Nat Biotechnol. 2010 Mar;28(3):203-7; author reply 207-11
20212477
Thromb Haemost. 2009 Nov;102(5):846-53
19888518
J Biol Chem. 2010 Jul 23;285(30):22966-75
20418371
J Pharm Biomed Anal. 2009 Apr 5;49(3):816-9
19179033
Thromb Haemost. 2009 Nov;102(5):892-9
19888525
Semin Thromb Hemost. 2001 Oct;27(5):473-82
11668416
Comp Biochem Physiol B. 1982;73(4):857-63
6817964
Carbohydr Res. 1989 Mar 15;186(2):301-12
2500236
Biochim Biophys Acta. 2000 Jul 26;1475(3):287-94
10913828
Thromb Haemost. 2009 Nov;102(5):907-11
19888527
Glycobiology. 2008 Mar;18(3):250-9
18174311
Glycobiology. 2007 Sep;17(9):983-93
17580314
N Engl J Med. 2008 Jun 5;358(23):2457-67
18434646
J Immunoassay Immunochem. 2001;22(4):323-36
11816801
J Pharm Sci. 2009 Nov;98(11):4017-26
19642166
Glycobiology. 2009 Jan;19(1):52-67
18832453
Thromb Haemost. 2009 Nov;102(5):874-8
19888522
Carbohydr Res. 2008 Aug 11;343(12):2184-93
18226804
Allergy. 1994 Aug;49(7):569-72
7825726
Biochem J. 1986 Jul 15;237(2):573-81
2948492
Biochemistry. 1989 Nov 14;28(23):8951-66
2690952
Infect Immun. 1984 Apr;44(1):91-6
6368395
J Clin Pharmacol. 2010 Oct;50(10):1159-70
20147614
J Pharm Biomed Anal. 2002 Jul 1;29(3):443-58
12062645
Talanta. 1998 Nov;47(3):525-30
18967354
J Clin Invest. 2001 Jul;108(2):169-73
11457867
Lancet. 1987 May 9;1(8541):1088
2883419